News and blogs
322 results found.
Insurance leader Matthew Wilson to be next chair of trustees of Blood Cancer UK
Blood Cancer UK will appoint insurance leader, and advisor to Fairfax Financial and Lloyd’s of London, Matthew Wilson as its next chair of trustees. Matthew will formally start his role in early 2024, as current chair John Ormerod’s term comes to an end after 5 years in post.
Amwins Global Risks partners with Blood Cancer UK to raise funds for myeloma
Blood Cancer UK has become Amwins Global Risks’ charity partner, with the partnership expected to raise around £100,000 in the next two years. The partnership will also raise the awareness of blood cancer, which is the third biggest cancer killer in the UK.
Stay updated with our organisational strategy
The latest news on our organisational strategy.
Research links childhood CT scan exposure to increased blood cancer risk
In new research, scientists have linked increased CT scan exposure to an increased risk of blood cancer in younger people.
How our research gave vaccine answers to people with blood cancer
As our QResearch project formally comes to a close, we look at how scientists were able to understand the effectiveness of the COVID-19 vaccine for clinically extremely vulnerable people during the pandemic.
The stolen legacy of Henrietta Lacks
Taken without her consent, Henrietta's "immortal" cells have had an everlasting contribution to research – while raising important issues around medical ethics and patients' rights. Henrietta's death was the start of a long battle for justice, but 70 years later, Henrietta's family finally received closure.
Non-Hodgkin lymphoma drug authorised for use in the UK
A drug for non-Hodgkin lymphoma, epcoritamab, has been authorised for use in the UK for adults.
This MDS World Awareness Day, four people share their story
October 25 every year is World MDS Awareness Day. This year, four people share their story of living with MDS.
Drug, zanubrutinib, now recommended for adults with CLL across the UK
Zanubrutinib has been recommended for adults with the blood cancer, chronic lymphocytic leukaemia (CLL) in England.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
We're calling for UK wide guidance for healthcare staff on masks and testing
As we head into winter, and COVID rates rising, we want to help protect those with blood cancer. We’re calling for UK-wide guidance to be reintroduced asking healthcare staff, to wear masks in clinical settings.
What we can achieve with £1 million
We're proud to announce We’ve invested over £1 million funding five research projects, across five different blood cancers
The story of Dr Jane C Wright, pioneer of blood cancer research
Born in 1919, Dr Wright transformed chemotherapy from an untested, experimental last resort, to a proven, effective blood cancer treatment. Throughout her career Jane overcame prejudice and other barriers to leave a legacy of millions of lives saved.
"Father of the blood bank" - Charles R. Drew's story
For Black History Month, we are celebrating Charles R. Drew who was an African American surgeon and researcher who pioneered in the field of blood transfusions, blood storage and created the first blood banks.
Charity welcomes Liberal Democrats leader’s cancer pledge after he revealed insight into blood cancer experience
Blood Cancer UK have welcomed the Lib Dem leaders cancer pledge after he revealed insight into blood cancer experience.
Myeloma combination therapy approved for use
The combination therapy, DRT, has been approved for use in England and Wales for those with myeloma who are not eligible for a stem cell transplant
Solomon's unexpected multiple myeloma diagnosis
After visiting his GP about a 'barely noticeable' lump on the side of his neck which was found to be benign, Solomon, who felt otherwise fit and well, was shocked to be diagnosed with a rare type of blood cancer – multiple myeloma – in 2018.
Ruxolitinib approved for treatment of polycythaemia vera in England and Wales
The drug, ruxolitinib, has been recommended for use by NICE to treat the blood cancer polycythaemia vera in those whose disease is resistant or intolerant to the treatments hydroxycarbamide/hydroxyurea.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
Clinical trials give a feeling of hope for those living with blood cancer
Rachel contacted the Clinical Trials Support Service to find out whether she could potentially take part in a clinical trial and contribute to blood cancer research.
